Although MG-induced pathology in wild-type mice reproduces key Alzheimer-like phenotypes, transgenic models (e.g., 5xFAD or APP/PS1) featuring genetically driven amyloid or tau pathology would further validate whether PG remains effective across broader AD mechanisms. The gene discussed is MAPT; the disease is amyloidosis.